Retraction Note: Long-term use of fluoxetine accelerates bone loss through the disruption of sphingolipids metabolism in bone marrow adipose tissue

Huili Zhang, Kefeng Li, Yanna Zhao, Yilan Zhang, Jiawen Sun, Shihong Li, Guangwu LinTranslational 2025 · DOI · OpenAlex

Overview

In October 2025, Translational Psychiatry officially retracted a 2020 study that proposed a specific biological mechanism for bone loss associated with long-term fluoxetine (Prozac) use. The original research suggested that fluoxetine accelerates bone loss by disrupting sphingolipid metabolism within bone marrow adipose tissue. However, significant concerns regarding data reliability—specifically within Figure 3I—led the journal and a majority of the authors to conclude that the study’s core findings are no longer tenable.

Context of the Original Research

The original study aimed to address a well-documented clinical observation: the link between selective serotonin reuptake inhibitors (SSRIs) and decreased bone mineral density. While the clinical association is known, the underlying molecular pathways have remained a subject of intense investigation. The 2020 paper sought to bridge this gap by identifying sphingolipid metabolism as a key mediator in how SSRIs influence bone health.

Reasons for Retraction

The retraction was prompted by post-publication scrutiny that identified critical issues with the integrity of the data presented.

  • Figure 3I Reliability: The journal explicitly identified Figure 3I as the primary source of concern. The nature of the discrepancies was deemed severe enough to compromise the integrity of the entire study's conclusions.
  • Author Disagreement: The retraction process revealed a lack of consensus among the research team. While Shihong Li, Guangwu Lin, Kefeng Li, and Yanna Zhao agreed to the retraction, the lead author, Huili Zhang, disagreed with the decision. This internal dissent highlights the complexities often involved in correcting the scientific record through post-publication peer review.

Impact on the Field

The formal nullification of these findings (Original Citation: Translational Psychiatry (2020) 10:144; DOI: 10.1038/s41398-020-0819-5) leaves a void in the current understanding of SSRI-induced bone loss. The proposed link between fluoxetine and sphingolipid disruption in bone marrow is no longer supported by validated evidence.

Conclusion and Future Directions

This retraction serves as a reminder of the binary nature of data integrity in high-impact research; a single compromised figure can invalidate an entire mechanistic model. For the scientific community, the challenge of explaining SSRI-related bone loss remains open. Future research must revisit these metabolic pathways with enhanced rigor and transparent data validation to ensure that any proposed mechanisms are reproducible and sound.

Summary updated

BibTeX
@inproceedings{zhang2025retraction,
  author = {Huili Zhang and Kefeng Li and Yanna Zhao and Yilan Zhang and Jiawen Sun and Shihong Li and Guangwu Lin},
  title = {{Retraction Note: Long-term use of fluoxetine accelerates bone loss through the disruption of sphingolipids metabolism in bone marrow adipose tissue}},
  booktitle = {Translational},
  year = {2025},
  doi = {10.1038/s41398-025-03711-x},
}
Figure